Bactolife, a start-up based in Copenhagen, Denmark, has raised over €30 million in Series B funding to accelerate the commercialisation of its precision-fermented Binding Proteins innovation.

The company describes its solution as a ‘revolutionary category of functional proteins’ that neutralises undesired metabolites and enhances gut resilience.

This latest funding round was led by Cross Border Impact Ventures and EIFO (Danish Export and Investment Fund), alongside continued support from existing investors Novo Holdings and Athos. It will enable Bactolife to commercialise its ingredient for the food, feed and dietary supplement market, and execute its human study programme, aimed at transforming human and animal health for proactive health management.

Supported by the investment, the start-up plans to launch its first Binding Protein products under the ingredient brand Helm in 2026, initially in the US. Bactolife plans to extend into Asia and Europe in the years that follow, aiming to make the technology accessible to women and children in low- and middle-income countries.

Binding Proteins are milk-inspired proteins that can help to maintain balance in the gastrointestinal system. They are inspired by camelid immunoglobins, which are produced naturally by the Camelidae family of mammals (including camels, llamas and alpacas).

Bactolife uses precision fermentation – a biotech method in which microorganisms are trained to produce certain targeted ingredients like animal-derived proteins, without the animal’s involvement – to produce and upscale the solution.

Sebastian Søderberg, CEO of Bactolife, said: “This funding will enable us to clinically validate, scale and commercialise our Binding Proteins, taking Bactolife’s solutions to a broad audience. We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission.”

The company now plans to scale its manufacturing and supply operations to meet global demand with the support of investors, with a strong focus on functional food and beverages and nutritional supplements, alongside feed additives.

Donna Parr, managing director at lead investor Cross Border Impact Ventures, commented: “Bactolife’s Binding Proteins have the potential to strengthen gut resilience for mothers and children in low- and middle-income countries by providing a scalable, food-grade solution that can be integrated into everyday nutrition”.

She added: “This investment reflects our conviction that evidence-based technologies can reach massive high-growth markets, inclusive of people who need them most, and we look forward to partnering with Bactolife to accelerate clinical validation, scale manufacturing, and expand equitable access globally”.